Experience in the use of targeted therapy in patients with radio-resistant forms of thyroid cancer  in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine

E. B. Vasil’eva; Васильева Е. Б.; A. V. Vazhenin; Важенин А. В.; T. M. Geliashvili; Гелиашвили Т. М.; N. V. Fadeeva; Фадеева Н. В.; A. V. Garev; Гарев А. В.; A. O. Guz’; Гузь А. О.

doi:10.17650/2222-1468-2018-8-1-24-27

Experience in the use of targeted therapy in patients with radio-resistant forms of thyroid cancer in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine

Authors: Vasil’eva E.B.¹, Vazhenin A.V.²^,3, Geliashvili T.M.¹, Fadeeva N.V.¹, Garev A.V.¹, Guz’ A.O.¹
Affiliations:
1. Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine.
2. Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
3. South Ural State Medical University, Ministry of Health of Russia.
Issue: Vol 8, No 1 (2018)
Pages: 24-27
Section: DIAGNOSIS AND TREATMENT OF HEAD AND NECK TUMORS
Published: 12.04.2018
URL: https://ogsh.abvpress.ru/jour/article/view/320
DOI: https://doi.org/10.17650/2222-1468-2018-8-1-24-27
ID: 320

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Radioiodine therapy of metastatic differentiated thyroid cancer is a highly effective method of treatment which makes it possible to achieve the complete cure of the majority of patients, however in some cases radioiodine refractory type develops, it leads to significant deterioration in overall and relapse-free survival. The article presents own experience of the therapy of radioiodine refractory thyroid cancer by the nexavar (sorafenib).